These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35505173)

  • 1. Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors.
    Lambo DJ; Lebedenko CG; McCallum PA; Banerjee IA
    Mol Divers; 2023 Feb; 27(1):389-423. PubMed ID: 35505173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide-conjugated glucosyloxy stilbene derivatives with tumor cell receptors.
    Rico MI; Lebedenko CG; Mitchell SM; Banerjee IA
    Mol Divers; 2022 Oct; 26(5):2717-2743. PubMed ID: 35037187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of binding interactions of tumor-targeted peptide conjugated polyphenols with the kinase domain of ephrin B4 and B2 receptors.
    Mitchell SM; Heise RM; Murray ME; Lambo DJ; Daso RE; Banerjee IA
    Mol Divers; 2024 Apr; 28(2):817-849. PubMed ID: 36847923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A computational and laboratory approach for the investigation of interactions of peptide conjugated natural terpenes with EpHA2 receptor.
    Goncalves BG; Banerjee IA
    J Mol Model; 2023 Jun; 29(7):204. PubMed ID: 37291458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
    Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
    Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.
    Zhao MY; Yin Y; Yu XW; Sangani CB; Wang SF; Lu AM; Yang LF; Lv PC; Jiang MG; Zhu HL
    Bioorg Med Chem; 2015 Jan; 23(1):46-54. PubMed ID: 25496804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
    Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
    Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico studies of interactions of peptide-conjugated cholesterol metabolites and betulinic acid with EGFR, LDR, and N-terminal fragment of CCKA receptors.
    Bashant MM; Mitchell SM; Hart LR; Lebedenko CG; Banerjee IA
    J Mol Model; 2021 Dec; 28(1):16. PubMed ID: 34961887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAF
    Hassan AA; Mohamed NK; Aly AA; Ramadan M; Gomaa HAM; Abdel-Aziz AT; Youssif BGM; Bräse S; Fuhr O
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursolic acid interaction with transcription factors BRAF, V600E, and V600K: a computational approach towards new potential melanoma treatments.
    Aguilera-Durán G; Hernández-Castro S; Loera-García BV; Rivera-Vargas A; Alvarez-Baltazar JM; Cuevas-Flores MDR; Romo-Mancillas A
    J Mol Model; 2024 Oct; 30(11):373. PubMed ID: 39387972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study.
    Das A; Biggs MA; Hunt HL; Mahabadi V; Goncalves BG; Phan CAN; Banerjee IA
    Mol Divers; 2024 Oct; ():. PubMed ID: 39424745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the structure-activity relationship of pyrimidine-sulfonamide analogues for targeting BRAF V600E protein.
    Srisongkram T; Tookkane D
    Biophys Chem; 2024 Apr; 307():107179. PubMed ID: 38241826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.
    Tang HC; Chen YC
    Int J Nanomedicine; 2015; 10():3131-46. PubMed ID: 25960652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF
    Marini E; Marino M; Gionfriddo G; Maione F; Pandini M; Oddo D; Giorgis M; Rolando B; Blua F; Gastaldi S; Marchiò S; Kovachka S; Spyrakis F; Gianquinto E; Di Nicolantonio F; Bertinaria M
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF
    Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R
    J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical Characterization of Full-Length Oncogenic BRAF
    Cope N; Novak B; Candelora C; Wong K; Cavallo M; Gunderwala A; Liu Z; Li Y; Wang Z
    Chembiochem; 2019 Nov; 20(22):2850-2861. PubMed ID: 31152574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.